Hartmut J. Ehrlich

Ehrlich, Hartmut J.

Hartmut J. Ehrlich, M.D., is Chief Executive Officer of Abivax. He is a physician with 30 years of experience in academia and in the biopharmaceutical industry. For 20 years, he worked on product development at Baxter and Sandoz — now Novartis. Before joining Abivax, as Head of Global R&D, he successfully built and advanced Baxter BioScience’s R&D portfolio with over 50 programs in preclinical and clinical development. He drove the regulatory approval of key biologics in the specialty areas of hemophilia, thrombosis, immunology, neurology, oncology, biosurgery and vaccines, thereby bringing novel therapies to patients with substantial medical needs. He also has authored or co-authored over 120 peer-reviewed articles and book chapters. In 2011, Dr. Ehrlich was named “Professor” by the Austrian President and the Austrian Minister for Science and Research, and he received the title of “Adjunct Professor” at the Danube University Krems, Lower Austria in 2013.